Supernus Pharma (SUPN) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Supernus Announces First Quarter 2016 Financial Results
May 3, 2016 5:00 PM EDTFirst quarter 2016 product prescriptions totaled 114,773, representing a 49.7% increase over the first quarter of 2015.Net product sales for first quarter 2016 were $43.0 million, a 53.1% increase over the first quarter of 2015.Operating income for first quarter 2016 was $5.3 million, a 55.0% increase over the first quarter of 2015.   Diluted earnings per share in the first quarter were $0.08 compared to $0.02 in the same period last year.   The Company remains on track to have data available from the Phase III program for SPN-810, for the treatment of Impulsive Aggression in ADHD, by mid-2017 and from the Phase IIb program for... More
